KR102316933B1 - 헌팅턴병 치료를 위한 프리도피딘의 용도 - Google Patents

헌팅턴병 치료를 위한 프리도피딘의 용도 Download PDF

Info

Publication number
KR102316933B1
KR102316933B1 KR1020167001531A KR20167001531A KR102316933B1 KR 102316933 B1 KR102316933 B1 KR 102316933B1 KR 1020167001531 A KR1020167001531 A KR 1020167001531A KR 20167001531 A KR20167001531 A KR 20167001531A KR 102316933 B1 KR102316933 B1 KR 102316933B1
Authority
KR
South Korea
Prior art keywords
delete delete
study
pridopidine
uhdrs
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167001531A
Other languages
English (en)
Korean (ko)
Other versions
KR20160055122A (ko
Inventor
메라브 바산
엘리 에얄
에스더 루카시에비치 하가이
안나 크리스티나 스베인스도터 타이게 비켄베르크
Original Assignee
프리레니아 뉴로테라퓨틱스 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102316933(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프리레니아 뉴로테라퓨틱스 엘티디. filed Critical 프리레니아 뉴로테라퓨틱스 엘티디.
Publication of KR20160055122A publication Critical patent/KR20160055122A/ko
Application granted granted Critical
Publication of KR102316933B1 publication Critical patent/KR102316933B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020167001531A 2013-06-21 2014-06-19 헌팅턴병 치료를 위한 프리도피딘의 용도 Active KR102316933B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US61/837,928 2013-06-21
US201361877832P 2013-09-13 2013-09-13
US61/877,832 2013-09-13
PCT/US2014/043204 WO2014205229A1 (en) 2013-06-21 2014-06-19 Use of high dose pridopidine for treating huntington's disease

Publications (2)

Publication Number Publication Date
KR20160055122A KR20160055122A (ko) 2016-05-17
KR102316933B1 true KR102316933B1 (ko) 2021-10-26

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167001531A Active KR102316933B1 (ko) 2013-06-21 2014-06-19 헌팅턴병 치료를 위한 프리도피딘의 용도

Country Status (24)

Country Link
US (1) US10322119B2 (https=)
EP (1) EP3010506B1 (https=)
JP (1) JP2016523862A (https=)
KR (1) KR102316933B1 (https=)
CN (1) CN105592848A (https=)
AU (1) AU2014281414A1 (https=)
BR (1) BR112015029918A2 (https=)
CA (1) CA2913781C (https=)
CL (1) CL2015003690A1 (https=)
DK (1) DK3010506T3 (https=)
EA (1) EA201690069A1 (https=)
ES (1) ES2879631T3 (https=)
HK (1) HK1221646A1 (https=)
HU (1) HUE054783T2 (https=)
IL (1) IL242804B (https=)
MX (1) MX384234B (https=)
PE (2) PE20160195A1 (https=)
PH (1) PH12015502691A1 (https=)
PL (1) PL3010506T3 (https=)
SG (1) SG11201509729YA (https=)
TW (1) TW201529069A (https=)
UA (1) UA122999C2 (https=)
UY (1) UY35624A (https=)
WO (1) WO2014205229A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20161220A1 (es) * 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA2993183A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
WO2018039475A1 (en) * 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) * 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
HRP20251431T1 (hr) * 2017-08-14 2026-01-02 Prilenia Neurotherapeutics Ltd. Liječenje amiotrofične lateralne skleroze pridopidinom
EP3675830A1 (en) 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3917380B1 (en) * 2019-01-31 2025-03-19 F. Hoffmann-La Roche AG Assessing progression of huntington's disease
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
JP7436524B2 (ja) * 2019-06-12 2024-02-21 プリレニア ニューロセラピューティクス リミテッド ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
US20220346699A1 (en) * 2019-09-17 2022-11-03 Hoffmann-La Roche Inc. Improvements in Personalized Healthcare for Patients with Movement Disorders
US20230390232A1 (en) * 2020-10-28 2023-12-07 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders
WO2025181805A1 (en) * 2024-02-27 2025-09-04 Prilenia Neurotherapeutics Ltd. Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150406A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH Hydrobromide salt of pridopidine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
HK1211525A1 (en) 2012-09-27 2016-05-27 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
PE20161220A1 (es) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) * 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150406A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH Hydrobromide salt of pridopidine

Also Published As

Publication number Publication date
HK1221646A1 (zh) 2017-06-09
DK3010506T3 (da) 2021-07-12
US10322119B2 (en) 2019-06-18
EP3010506A4 (en) 2017-02-08
EP3010506A1 (en) 2016-04-27
KR20160055122A (ko) 2016-05-17
MX2015017307A (es) 2016-08-03
MX384234B (es) 2025-03-14
PH12015502691A1 (en) 2016-03-14
PL3010506T3 (pl) 2021-11-02
UA122999C2 (uk) 2021-02-03
JP2016523862A (ja) 2016-08-12
PE20170302A1 (es) 2017-03-31
PE20160195A1 (es) 2016-05-14
TW201529069A (zh) 2015-08-01
ES2879631T3 (es) 2021-11-22
CA2913781C (en) 2022-05-10
US20140378508A1 (en) 2014-12-25
EA201690069A1 (ru) 2016-06-30
UY35624A (es) 2015-01-30
WO2014205229A1 (en) 2014-12-24
SG11201509729YA (en) 2015-12-30
CL2015003690A1 (es) 2016-10-28
CA2913781A1 (en) 2014-12-24
IL242804B (en) 2022-02-01
WO2014205229A8 (en) 2015-04-09
AU2014281414A1 (en) 2016-01-21
BR112015029918A2 (pt) 2017-07-25
HUE054783T2 (hu) 2021-09-28
EP3010506B1 (en) 2021-05-12
CN105592848A (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
KR102316933B1 (ko) 헌팅턴병 치료를 위한 프리도피딘의 용도
US20250360121A1 (en) Pridopidine for treating huntington's disease
US20250352533A1 (en) Pridopidine for treating huntington's disease
JP2021119189A (ja) ジストニアを治療するためのプリドピジンの使用
JP2022524008A (ja) うつ病の治療のためのエスケタミン
KR20220079859A (ko) 에스케타민의 비강내 투여
Zacny et al. Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers
KR20210153059A (ko) 중수소화 덱스트로메토르판 및 퀴니딘을 사용하는 정신분열병의 음성 증상의 치료 방법
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
TW201242600A (en) Treatment of cognitive dysfunction in schizophrenia
Bharucha et al. Assessment of behavioral and psychological symptoms of dementia
Diamond Instant Psychopharmacology 3e
JP2024540104A (ja) アルツハイマー病に関連する激越を治療する方法
CN119654149A (zh) 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
Class et al. Patent application title: PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE
HK1224215A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
Koran Treatment of patients with obsessive-compulsive disorder
HK40089955A (zh) 治疗与阿尔茨海默氏病相关的激越的方法
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
EA039995B1 (ru) Применение придопидина для лечения болезни хантингтона
EA041256B1 (ru) Применение придопидина для лечения ухудшения функциональной способности
Jawahar Pain Management and Menopausal Health Outcomes in Multiple Sclerosis
KOVARIK ficient clinical pharmacology information." 2 This exercise is of particular relevance to

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190530

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200218

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201110

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210525

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201110

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210525

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210111

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190530

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210802

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210726

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210525

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210111

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190530

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211019

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211020

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240919

Start annual number: 4

End annual number: 4